A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- NSCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Last updated on ClinicalTrials.gov
- January 3, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Indiana · 1
- Horizon Oncology · Lafayette, IN
Texas · 1
- Next Oncology · San Antonio, TX
Washington · 1
- Summit Cancer Centers · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.